Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2005

View Archived Issues

17-DMAG induces cytostasis in testicular teratocarcinoma cells

Atorvastatin shows potential as a chemopreventive agent

ED-B targeted therapy L19-IL2 effective in pancreatic cancer model

In vivo and in vitro data on ZP-120 reported

Bristol-Myers Squibb profiles Q1 developments

NDA submitted for indiplon tablets

Santarus submits Zegerid chewable tablets NDA

Second clinical study completed for E-Matrix

Data demonstrates wound healing effects of TB4

Myogen and Novartis expand cardiac drug discovery collaboration

Discovery and antitumor efficacy of ABT-737, a Bcl-2 blocker

Antitumor and antiangiogenic effects of the class III/V tyrosine kinase inhibitor SU-11657 in mice

IC-486051: a novel PDE4 inhibitor for overactive bladder treatment

Novel PDE4 inhibitor/M3 antagonist evaluated in preclinical models of COPD

JPM7 induces strong and fast rabbit tracheal muscle relaxation

Uracyst launched in U.K.

New approval for Arixtra

Vivitrex NDA accepted for priority review

Long-term benefits of Cypher stents in patients with coronary artery disease

Zemplar capsules receive FDA approval

Promising alternative to injectable anthrax vaccine

Additional data on efficacy of exenatide in patients with type 2 diabetes

Role of interleukin-13 in the pathogenesis of eosinophilic esophagitis

Flavonoid derivative suppresses NF-kappaB activation in human colonic epithelial cells

Alnylam and U of Georgia to develop RNAi therapeutic for flu

In vivo data on kallikreins in ovarian cancer reported by Ibex

Ablynx and NRC to develop Nanobodies for CNS diseases

New urological agents reported

New treatment option for anxiety and depression claimed by Roche

Recent Kosan patents cover therapeutic agents for gastric motility disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...